FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Dag Clement Johannessen

Research Profile

Disorders

Chemicals & Drugs

Physiology

Postmenopause

Concepts & Ideas

Co-author Network

Publications

TOP 3
Sten Nilsson; Charles Gillies O'Bryan-Tear; Christopher Parker; Ulf Petersson; Katharine Pigott; Michael Sokal; Jan Tennvall; Marcus Thuresson; Christopher Tyrrell; René Blom; Bjørg Bolstad; Lars Franzén; Dag Clement Johannessen; Bo Lennernäs; Oyvind S Bruland
Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases.
Trond-Eirik Strand; Paal Fredrik Brunsvig; Dag Clement Johannessen; Stein Sundstrøm; Mari Wang; Kjersti Hornslien; Roy M Bremnes; Andreas Stensvold; Oddveig Garpestad; Jarle Norstein
Potentially curative radiotherapy for non-small-cell lung cancer in Norway: a population-based study of survival.
Asa Karlsdottir; Ludvig Paul Muren; Tore Wentzel-Larsen; Dag Clement Johannessen; Svein A Haukaas; Ole Johan Halvorsen; Olav Dahl
Outcome in intermediate or high risk prostate cancer patients receiving radiation dose and hormone therapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Dag Clement Johannessen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Sten Nilsson; Charles Gillies O'Bryan-Tear; Christopher Parker; Ulf Petersson; Katharine Pigott; Michael Sokal; Jan Tennvall; Marcus Thuresson; Christopher Tyrrell; René Blom; Bjørg Bolstad; Lars Franzén; Dag Clement Johannessen; Bo Lennernäs; Oyvind S Bruland
Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases.
Clinical genitourinary cancer 2013;11(1):20-6.
2011: Trond-Eirik Strand; Paal Fredrik Brunsvig; Dag Clement Johannessen; Stein Sundstrøm; Mari Wang; Kjersti Hornslien; Roy M Bremnes; Andreas Stensvold; Oddveig Garpestad; Jarle Norstein
Potentially curative radiotherapy for non-small-cell lung cancer in Norway: a population-based study of survival.
International journal of radiation oncology, biology, physics 2011;80(1):133-41.
2009: Asa Karlsdottir; Ludvig Paul Muren; Tore Wentzel-Larsen; Dag Clement Johannessen; Svein A Haukaas; Ole Johan Halvorsen; Olav Dahl
Outcome in intermediate or high risk prostate cancer patients receiving radiation dose and hormone therapy.
Acta oncologica (Stockholm, Sweden) 2009;48(6):874-81.
2008: Ludvig Paul Muren; Ellen Wasbø; Svein Inge Helle; Liv Bolstad Hysing; Asa Karlsdottir; Odd Harald Odland; H Valen; Randi Ekerold; Dag Clement Johannessen
Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: planning procedures and early experiences.
International journal of radiation oncology, biology, physics 2008;71(4):1034-41.
2007: Sten Nilsson; Lars Franzén; Christopher Parker; Christopher Tyrrell; René Blom; Jan Tennvall; Bo Lennernäs; Ulf Petersson; Dag Clement Johannessen; Michael Sokal; Katharine Pigott; Jeffrey Yachnin; Michael Garkavij; Peter Strang; Johan Harmenberg; Bjørg Bolstad; Oyvind S Bruland
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.
The lancet oncology 2007;8(7):587-94.
2006: Asa Karlsdottir; Paul Ludvig Muren; Tore Wentzel-Larsen; Dag Clement Johannessen; August Bakke; Per Ogreid; Ole Johan Halvorsen; Olav Dahl
Radiation dose escalation combined with hormone therapy improves outcome in localised prostate cancer.
Acta oncologica (Stockholm, Sweden) 2006;45(4):454-62.
2004: Asa Karlsdóttir; Dag Clement Johannessen; Ludvig Paul Muren; Tore Wentzel-Larsen; Olav Dahl
Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2004;71(1):43-53.
2004: Stein Sundstrøm; Roy M Bremnes; Ulf Aasebø; Steinar Aamdal; Reidulv Hatlevoll; Paal Brunsvig; Dag Clement Johannessen; Olbjørn Klepp; Peter M Fayers; Stein Kaasa
Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):801-10.
2002: Sophie D Fosså; Sigmund Vaage; Henry Letocha; Jon Iversen; Terje Risberg; Dag Clement Johannessen; Elisabeth Paus; Trond Smedsrud
Liposomal doxorubicin (Caelyx) in symptomatic androgen-independent prostate cancer (AIPC)--delayed response and flare phenomenon should be considered.
Scandinavian journal of urology and nephrology 2002;36(1):34-9.
2001: Per Eystein Lønning; Jürgen Geisler; Dag Clement Johannessen; Hans-Peter Gschwind; Felix Waldmeier; W Schneider; B Galli; T Winkler; W Blum; H P Kriemler; W R Miller; J W Faigle
Pharmacokinetics and metabolism of formestane in breast cancer patients.
The Journal of steroid biochemistry and molecular biology 2001;77(1):39-47.
1999: Gun Anker; Helga Refsum; Per Magne Ueland; Dag Clement Johannessen; Ernst A Lien; PE Lonning
Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients.
Clinical chemistry 1999;45(2):252-6.
1998: H Berntsen; Per Eystein Lønning; Dagfinn Ekse; B Netteland; Dag Clement Johannessen; R Berge; A Svardal
Influence of treatment with aminoglutethimide on plasma and red-blood-cell glutathione status in breast cancer patients.
Cancer chemotherapy and pharmacology 1998;42(1):46-52.
1997: Dag Clement Johannessen; T Engan; E di Salle; MG Zurlo; Jolanda Paolini; G Ornati; G Piscitelli; S Kvinnsland; PE Lonning
Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(7):1101-8.
1997: Per Eystein Lønning; Jürgen Geisler; Dag Clement Johannessen; Dagfinn Ekse
Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate.
The Journal of steroid biochemistry and molecular biology 1997;61(3-6):255-60.
1996: Jürgen Geisler; Dag Clement Johannessen; Gun Anker; Per Eystein Lønning
Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects.
European journal of cancer (Oxford, England : 1990) 1996;32A(5):789-92.
1996: Per Eystein Lønning; Svein Inge Helle; Dag Clement Johannessen; Dagfinn Ekse; H Adlercreutz
Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer.
Breast cancer research and treatment 1996;39(3):335-41.
1995: Per Eystein Lønning; Dag Clement Johannessen; Ernst A Lien; Dagfinn Ekse; Theodore Fotsis; H Adlercreutz
Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients.
The Journal of steroid biochemistry and molecular biology 1995;52(5):491-6.
1995: T Engan; Jostein Krane; Dag Clement Johannessen; Per Eystein Lønning; S Kvinnsland
Plasma changes in breast cancer patients during endocrine therapy--lipid measurements and nuclear magnetic resonance (NMR) spectroscopy.
Breast cancer research and treatment 1995;36(3):287-97.
1995: Per Eystein Lønning; Svein Inge Helle; Dag Clement Johannessen; H Adlercreutz; Ernst A Lien; Michael Tally; Dagfinn Ekse; Theodore Fotsis; Gun Anker; K Hall
Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients.
Clinical endocrinology 1995;42(1):23-30.
1993: Dag Clement Johannessen; H Adlercreutz; Theodore Fotsis; Per Eystein Lønning
Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.
British journal of cancer 1993;68(2):393-8.
1992: Dag Clement Johannessen; Per Eystein Lønning
Aromatase inhibitors in malignant diseases of aging.
Drugs & aging 1992;2(6):530-45.
1992: Ernst A Lien; Dag Clement Johannessen; A Aakvaag; Per Eystein Lønning
Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients.
The Journal of steroid biochemistry and molecular biology 1992;41(3-8):541-3.
1992: Per Eystein Lønning; Mitch Dowsett; A Jones; Dagfinn Ekse; S Jacobs; F McNeil; Dag Clement Johannessen; T J Powles
Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment.
Breast cancer research and treatment 1992;23(1-2):57-62.
1989: Per Eystein Lønning; Dag Clement Johannessen; Thor Thorsen; Dagfinn Ekse
Effects of aminoglutethimide on plasma estrone sulfate not caused by aromatase inhibition.
Journal of steroid biochemistry 1989;33(4A):541-5.
1989: Per Eystein Lønning; Dag Clement Johannessen; Thor Thorsen
Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide.
British journal of cancer 1989;60(1):107-11.